P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

NCT03288493 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

105

Enrollment

INDUSTRY

Sponsor class

Stopped Phase I portion of the study was completed. The phase II portion of the study was terminated early to focus on an Allogeneic BCMA CAR-T program.

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: P-BCMA-101 CAR-T cells
DRUG: Rimiducid

Sponsor

Poseida Therapeutics, Inc.

Collaborators

[object Object]